Study on NLP+AI Feedback for Shared Decision-Making in Prostate Cancer
This study is looking at how a special feedback system, called NLP+AI Report, can help men with newly diagnosed localized prostate cancer and their doctors make better treatment decisions together. The NLP+AI Report uses natural language processing (NLP) and artificial intelligence (AI) to summarize important parts of doctor-patient conversations. These summaries are then shared with patients and doctors. The study wants to see if this feedback helps patients feel more confident in their treatment choices and improves how doctors talk about risks and benefits. Men aged 18 and older who are having their first consultation for localized prostate cancer may be able to join. The study aims to enroll 283 participants, but the current status of recruitment is unclear.
- Study design
- This is a randomized study where 259 patients will be grouped within 24 doctors. Some will receive standard care, while others will also get the NLP+AI Report feedback.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 2-4 weeks after diagnosis and enrollment to measure decisional conflict, shared decision-making, and appropriateness of treatment choice.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Decisional conflict2-4 weeks (from diagnosis and enrollment through the completion of post feedback survey)
Decisional conflict is a patient-level outcome between intervention and control and will be measured using the validated Decisional Conflict Scale (DCS) questionnaire, where participants will list if they strongly agree, agree, neither, disagree, or strongly disagree with the provided statements
- Shared decision-making2-4 weeks (from diagnosis and enrollment through the completion of post feedback survey
Shared decision making will be patient-reported and measured using the validated SDMP-4 questionnaire.
- Appropriateness of treatment choice2-4 weeks (from diagnosis and enrollment through the completion of post feedback survey)
Appropriateness of treatment choice will be determined a priori based on previously published measures determined by treatment guidelines.
- Quality of risk communication6-9 months (post study analysis)
Physician level outcome-that will measure the difference in composite quality of physician risk communication between the experimental and control arms. Quality of physician risk communication will be measured using a previously published hierarchical scale that is specific to communication of cancer prognosis, life expectancy, and treatment-related side effects.